ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, BCR-ABL1 kinase domain mutations that were associated with TKI-resistance were also observed in 15% of CML patients with the BIM deletion polymorphism who experienced sub-optimal TKI responses [1].